CBU
SYRE icon

CIBC Bancorp USA’s Spyre Therapeutics SYRE Stock Holding History

CIBC Bancorp USA’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Buy
+4,122
New +$301K ﹤0.01% 1442

Other funds holding SYRE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

CIBC Bancorp USA's SYRE Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 4,122 shares worth $366K. The stake represents ﹤0.01% of the portfolio and ranks #1442 among its holdings.

237 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • CIBC Bancorp USA held 4,122 shares of Spyre Therapeutics worth $366K as of Q2 2026.
  • Spyre Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1442 holding.
  • 237 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.